What were the primary outcomes of the JPAD trial?
The primary outcome of the JPAD trial was the occurrence of atherosclerotic events (fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease). There was no effect of aspirin on the primary end point (HR, 0.80; 95% CI, 0.58 1.10; P=0.16) and no effect on cerebrovascular events (2.2% with aspirin versus 2.5% with no aspirin; HR, 0.84; 95% CI, 0.53 1.32; P=0.44). There was no difference in the combined rates of hemorrhagic stroke and severe gastrointestinal bleeding.